Intravenous Anesthetics

Introduction/Overview

Intravenous anesthetics constitute a pivotal class of agents employed to achieve rapid, reversible loss of consciousness and analgesia during surgical and procedural interventions. Their pharmacological versatility permits tailored induction, maintenance, and recovery profiles that align with diverse clinical scenarios. Understanding the fundamental properties of these drugs is essential for safe application, optimal patient outcomes, and the mitigation of adverse events. The following objectives guide the reader through the essential aspects of intravenous anesthetics:

• Identify the principal drug classes and their chemical characteristics.
• Explain the primary mechanisms of action at receptor and cellular levels.
• Describe key pharmacokinetic parameters influencing dosing and monitoring.
• Outline approved therapeutic uses and common off‑label applications.
• Recognize major adverse effects, drug interactions, and special patient considerations.

Classification

GABA_A Receptor Modulators

Agents that potentiate inhibitory gamma‑aminobutyric acid (GABA) signaling via the GABA_A chloride channel are the most widely utilized intravenous anesthetics. This group includes:

• Propofol – a highly lipophilic phenol derivative.
• Etomidate – an imidazole analogue with minimal cardiac depression.
• Thiopental – a barbiturate with rapid onset and short duration.
• Alfaxolone – a synthetic neurosteroid with selective GABA_A modulation.

NMDA Receptor Antagonists

Ketamine, a dissociative anesthetic, exerts its primary effect by antagonizing N‑methyl‑D‑aspartate (NMDA) receptors, thereby inducing a distinct anesthetic state characterized by dissociation and analgesia.

Opioid‑Based Sedatives

High‑potency opioids such as fentanyl and remifentanil, when combined with other agents, can provide profound sedation with rapid onset and short duration of action.

Other Classes

Barbiturates (e.g., phenobarbital), benzodiazepine derivatives (e.g., midazolam), and novel agents (e.g., esketamine, clonidine) also contribute to the intravenous anesthetic arsenal, albeit less frequently in primary anesthetic roles.

Mechanism of Action

GABA_A Receptor Potentiation

Propofol, etomidate, and other lipophilic agents bind to distinct allosteric sites on the GABA_A receptor complex, enhancing chloride ion influx and hyperpolarization of neuronal membranes. This potentiation suppresses excitatory neurotransmission, leading to global cortical depression and unconsciousness. The precise binding sites differ among agents: propofol interacts with the β subunit, etomidate with the α1 subunit, and thiopental with the γ subunit, accounting for divergent hemodynamic profiles.

NMDA Receptor Antagonism

Ketamine competitively inhibits NMDA receptors, preventing calcium influx and excitatory signaling. The blockade yields dissociative anesthesia, analgesia, and sympathomimetic effects, which can be advantageous in hypovolemic or cardiac‑stressed patients.

Opioid Receptor Activation

Fentanyl and remifentanil act as μ‑opioid receptor agonists, increasing potassium conductance and inhibiting calcium influx in afferent nociceptive pathways. When used as adjuncts, they enhance sedation and analgesia while allowing lower doses of GABAergic agents.

Neurosteroid Modulation

Alfaxolone and related neurosteroids bind to the neurosteroid site on the GABA_A receptor, yielding rapid onset and a relatively short duration while preserving hemodynamic stability.

Pharmacokinetics

Absorption

Intravenous administration ensures 100 % bioavailability; thus, absorption is not a limiting factor. Rapid distribution into highly perfused tissues accounts for the swift onset of action.

Distribution

Highly lipophilic agents such as propofol and ketamine achieve extensive distribution into adipose tissues, the central nervous system, and the myocardium. Lipid solubility correlates with the depth and duration of anesthesia. Protein binding ranges from moderate (propofol ~80 %) to high (thiopental >90 %), influencing the free fraction available for receptor interaction.

Metabolism

Propofol undergoes conjugation via glucuronidation in the liver, producing inactive metabolites that are excreted renally. Thiopental and etomidate are metabolized by hepatic microsomal oxidation. Ketamine is metabolized by CYP2B6 to norketamine, which retains partial pharmacologic activity.

Excretion

Metabolites are primarily eliminated through the kidneys. Renal impairment may prolong the terminal half‑life of propofol metabolites, whereas hepatic dysfunction can delay clearance of ketamine and etomidate. Remifentanil is uniquely metabolized by non‑specific plasma and tissue esterases, yielding a remarkably short half‑life irrespective of organ function.

Half‑Life and Dosing Considerations

Propofol has an effective half‑life of 4–6 min and a terminal half‑life of 2–3 h. Ketamine’s effective half‑life is 10–15 min, with a terminal half‑life of 2–3 h. Etomidate’s effective half‑life is 2–3 min, terminal half‑life ~1 h. Adjustments in the initial loading dose and infusion rates are guided by patient age, comorbidities, and desired depth of anesthesia. Continuous monitoring of hemodynamic parameters and depth of anesthesia (e.g., BIS monitoring) is recommended to tailor dosing dynamically.

Therapeutic Uses/Clinical Applications

Induction of General Anesthesia

Propofol and etomidate are preferred for rapid sequence induction due to their quick onset and predictable pharmacodynamics. Ketamine may be selected in patients with hypotension or compromised cardiac function because of its sympathomimetic properties.

Maintenance of Anesthesia

Low‑dose propofol infusions, often combined with remifentanil, provide steady sedation with minimal respiratory depression. Etomidate infusions are used for prolonged surgeries requiring hemodynamic stability.

Procedural Sedation

Ketamine and propofol are frequently employed for conscious sedation in endoscopic or interventional radiology procedures. Fentanyl or remifentanil, in conjunction with propofol, offers deep sedation with rapid recovery.

ICU Sedation

Remifentanil, owing to its ultra‑short action, is advantageous in mechanically ventilated patients requiring frequent neurological assessment. Propofol infusions are also common but may be limited by propofol infusion syndrome in prolonged use.

Off‑Label Applications

Low‑dose ketamine has been investigated for refractory depression and acute pain management. Propofol has been used off‑label for procedural sedation in pediatric patients and for the treatment of status epilepticus. Caution is warranted, and institutional protocols should be followed.

Adverse Effects

Common Side Effects

• Hypotension – most pronounced with propofol and etomidate.
• Bradycardia – frequently observed with propofol; mitigated by anticholinergic premedication.
• Respiratory Depression – dose‑dependent; monitored closely during sedation.
• Myoclonus – typical with propofol; may be minimized by slower infusion rates.
• Post‑operative nausea and vomiting (PONV) – common with propofol and ketamine.

Serious or Rare Reactions

• Propofol Infusion Syndrome (PRIS) – characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure; associated with high‑dose, prolonged infusions.
• Adrenal Suppression – etomidate can transiently inhibit 11β‑hydroxylase, reducing cortisol synthesis.
• Coronary Vasospasm – reported with ketamine, especially at high concentrations.
• Seizures – rare with ketamine, more common with propofol withdrawal.

Black Box Warnings

Propofol carries a warning regarding PRIS, advising against continuous infusions exceeding 4 mg/kg/h for more than 48 h. Etomidate’s potential for adrenal suppression is also highlighted, particularly in patients requiring prolonged anesthesia.

Drug Interactions

Major Interactions

• Anticholinergics – reduce propofol‑induced bradycardia but may increase hypotension.
• Neuromuscular Blocking Agents – synergize with propofol to enhance muscle relaxation; dosing of agents such as rocuronium may need adjustment.
• Opioids – fentanyl or remifentanil potentiates respiratory depression and hypotension when combined with propofol.
• Cytochrome P450 Inhibitors/Inducers – affect metabolism of ketamine and etomidate; hepatic enzyme inhibitors may prolong effects.

Contraindications

• Severe hepatic or renal failure may necessitate avoidance or dose reduction of propofol and etomidate.
• Known hypersensitivity to the drug or excipients (e.g., propofol contains soybean oil).
• Patients with severe hyperlipidemia or pancreatitis may be at increased risk with lipid‑based formulations.

Special Considerations

Pregnancy and Lactation

Propofol is considered category B; limited data exist for ketamine, which may cross the placenta. Etomidate’s adrenal suppression raises concerns in pregnancy, particularly in the first trimester. Excretion into breast milk is minimal for propofol; ketamine metabolites may be present in negligible amounts.

Pediatric and Geriatric Populations

• Pediatrics – lower body water and higher lipid content can influence distribution; propofol dosing must be weight‑adjusted.
• Geriatrics – decreased hepatic clearance and altered protein binding may prolong half‑life; careful titration is advised.

Renal and Hepatic Impairment

Propofol’s hepatic metabolism necessitates caution in cirrhosis. Ketamine’s metabolites may accumulate in renal failure, potentially prolonging the anesthetic effect. Etomidate’s metabolism is less hepatic, but caution remains warranted in severely impaired patients.

Cardiovascular Instability

Ketamine’s sympathomimetic effects are advantageous in hypotensive patients, whereas propofol and etomidate require vasopressor support during induction in those with compromised cardiac output.

Summary/Key Points

• Intravenous anesthetics are classified chiefly by their primary receptor targets: GABA_A modulators, NMDA antagonists, and opioid agonists.
• The rapid onset of action is attributed to high lipid solubility and swift distribution to central nervous tissues.
• Metabolism predominantly occurs in the liver; propofol undergoes glucuronidation, whereas ketamine and etomidate are oxidatively metabolized.
• Propofol remains the most widely used induction agent, while ketamine is preferred in hemodynamically unstable patients.
• Adverse effects such as hypotension, bradycardia, and PRIS require vigilant monitoring and dose titration.
• Drug interactions, particularly with opioids and neuromuscular blockers, necessitate careful adjustment of dosing regimens.
• Special patient populations, including pregnant, pediatric, geriatric, and those with organ dysfunction, require individualized dosing strategies and monitoring protocols.
• Adherence to institutional guidelines and the use of depth‑of‑anesthesia monitoring tools can optimize safety and efficacy.
• Continued research into novel agents and refined dosing algorithms promises to enhance the therapeutic index of intravenous anesthetics.

References

1. Flood P, Rathmell JP, Urman RD. Stoelting's Pharmacology and Physiology in Anesthetic Practice. 6th ed. Philadelphia: Wolters Kluwer; 2022.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.